Sean Marett

CBO and CCO BioNTech SE

Sean Marett joined BioNTech SE in 2012 as Chief Business and Chief Commercial Officer. Prior to joining BioNTech, he worked in global strategic and regional marketing and sales roles at GlaxoSmithKline in the United States and Pfizer in Europe before taking business development executive roles at Evotec and Lorantis (sold to Celldex Therapeutics, Inc). Amongst his duties at BioNTech, Mr Marett has been responsible for licensing transactions, acquisitions and fundraising resulting in capital inflows into BioNTech of $1.5 billion. Whilst at BioNTech, Mr Marett has been Chairman of PHMR Ltd, a company specializing in market access and pharmaceutical reimbursement (sold to UDG Healthcare) and was non-executive director of KWS BioTest Ltd (sold to Charles River). He holds a BSc (Hons) in Biochemistry from Kings College London and an MBA from Manchester Business School.